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Effect of intravenous glucagon on intestinal 
viability after segmental mesenteric ischemia 
Sidhu P. Gangadharan, BS, ~ Robert  J. Wagner, BS, and 
Jack L. Cronenwett,  MD, Lebanon, N.H. 
Purpose: We have previously shown that intravenous glucagon significantly improves rat 
survival if given after release of superior mesenteric artery occlusion. The purpose of this 
study was to isolate the effects of glucagon on the intestine by creating a rat model of 
segmental mesenteric ischemia that avoids the systemic shock associated with total 
superior mesenteric artery occlusion and reperfusion. 
Methods: In 18 anesthetized Sprague-Dawley rats, an 8 cm segment ofmidileum was made 
totally ischemic for 110 minutes by occluding its vascular arcades and the bowel ends with 
microvascular clamps. Control animals (n = 8) received normal saline solution (10 
ml/kg/hr intravenously) during ischemia nd for 2 hours after declamping. Ten animals 
also received glucagon (1 p~g/kg/min i travenously) during 2 hours after deelamping. After 
a 24-hour ecovery, the ischemic bowel segment, plus nonischemic proximal ileum, was 
examined histologically by computerized planimetry to measure wall thickness (muscu- 
laris, mucosa, and transmural), percent epithelial coverage, and villar surface ratio (villar 
surface length/bowel circumference). All observations were blinded. Comparisons were 
made by Student's t test. 
Results: Compared with nonischemic ileum, the ischemic segment in control animals 
showed severe mucosal injury with a reduction in mucosal thickness to 25%, epithelial 
coverage to 23%, and villar surface ratio to 33% of that seen in nonischemic ileum 
(p < 0.01). Substantial preservation fileal mucosal viability was seen in glucagon-treated 
animals. Mucosal thickness and epithelial coverage were twice as well preserved in 
glucagon-treated rats compared with control rats (p < 0.05), and villar surface ratio was 
also increased significantly (p < 0.05). The muscularis was not significantly injured in this 
model. 
Conclusions: By use of quantitative histologie measurements, wefound that intravenous 
glucagon significantly improved ileal mucosal viability when given early during reperfu- 
sion after segmental ischemia. The mechanism of this effect and its potential clinical 
application merit further study. (J VAsc SURG 1995;21:900-8.) 
Despite ffective surgical treatment, the mortality 
rate for patients with acute occlusive mesenteric 
ischemia remains high because of delays in diagnosis 
and definitive treatment? In an attempt o improve 
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survival after acute mesenteric schemia, anumber of 
experimental studies have tested various pharmaco- 
logic agents that might improve intestinal blood flow 
as an adjunct to surgical revascularization. I  this 
regard, we have been particularly interested in 
glucagon, because of its relatively selective mesenteric 
vasodilating properties and positive cardiac inotropic 
effects when administered intravenously. 2 
In a series of  studies comparing several vasoactive 
agents, intravenous glucagon was the most effective 
drug for improving rat survival after acute occlusive 
mesenteric schemia. 3-s In this rat model, 85 minutes 
of total superior mesenteric artery (SMA) occlusion 
results in only 17% to 33% survival without treat- 
ment or with saline solution alone. 3 Intravenous 
glucagon (1 ~g/kg/min) improved survival to 83% in 
this model, if given for 2 hours after release of SMA 
occlusion) Because survival is used as an end point, 
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however, this model does not directly assess the 
degree of intestinal injury but rather the net effect of 
intestinal shock on the entire animal. In fact, our 
hemodynamic measurements in these rats indicate 
that cardiac output decreases markedly during intes- 
tinal reperfusion, and glucagon administered during 
this interval prevents the resultant shock. 6This raises 
the question of whether total SMA occlusion and 
reperfusion i  the rat model are analogous to human 
occlusive mesenteric ischemia, in which intestinal 
infarction and associated sepsis are usually responsi- 
ble for death rather than acute cardiac decompensa- 
Lion. Furthermore, it is unclear from these rat survival 
studies whether the principal effect of glucagon is 
direct cardiac inotropic support or selective mesen- 
teric vasodilation, with resultant reduction of ongo- 
ing release of myocardial-depressant f c ors. 
Because of these questions, we designed this 
study to investigate the effect of intravenous gluca- 
gon on intestinal viability per se, after acute occlusive 
ischemia. To accomplish this, we used a rat model of 
segmental ischemia in which less than 10% of the 
entire small intestine was rendered totally ischemic. 
This degree of segmental ischemia did not result in 
significant mesenteric shock, because animals sur- 
vived at least 24 hours. This model allowed histologic 
examination of the ischemic intestine in surviving 
animals, which was not possible in our previous 
studies of total SMA occlusion because of the high 
mortality rate without treatment. We chose a long 
(110 minutes) interval of segmental ischemia to 
produce a severe challenge in which to test the 
potential benefit of glucagon and developed quanti- 




Fasting male Sprague-Dawley rats (n = 18; 240 
to 670 gm) were anesthetized with ketamine and 
pentobarbital (60 mg/kg and 21 mg/kg intraperito- 
neally, respectively). One jugular vein was cannulated 
and an infusion of normal saline solution (10 
ml/kg/hr) was begun. Rectal temperature was moni- 
tored and maintained at 38 ° C with a servo-controlled 
heating pad. A midline laparotomy was used to 
expose the small bowel, which was moistened con- 
tinuously with saline solution to prevent desiccation 
during manipulation. An 8 cm segment of midileum 
(representing 8.5% of the total length of small 
intestine in these rats) was then made totally ischemic 
for 110 minutes (+_ 10 minutes) by occlusion of both 
the vascular arcades and the proximal and distal 
bowel ends of this segment with microvascular 
clamps. Pilot studies had demonstrated that an 
ischemic interval r nging from I05 to 120 minutes 
was adequate to cause severe, reproducible ischemia 
in this segment while still resulting in animal survival 
beyond 24 hours. After the placement of these 
microvascular clamps, the entire intestine was re- 
turned to the abdomen during the i10-minute 
ischemic interval. At the end of this time, the 
microvascular damps were removed and the nds of 
the ischemic segment were marked with 7-0 suture 
for later identification. 
Control animals (n = 8; 345 ___ 53 gm SEM) 
received only normal saline solution (10 ml/kg/hr) 
during the ischemic interval and for 2 hours after 
declamping. Ten animals (388 _+ 49 gm SEM) also 
received glucagon (1 txg/kg/min intravenously) for 2 
hours during intestinal reperfusion, immediately 
after dedamping. The investigator performing the 
experiment was bfinded as to the treatment, which 
was randomized to prevent any bias during the study. 
The abdominal incision was closed early during 
reperfusion. After 2 hours of drug/saline infusion, the 
jugular vein catheter was removed, the neck incision 
was closed, and the animals were allowed to recover 
with food and water ad libitum. After 24 hours of 
reperfusion, the rats were reanesthetized, the abdo- 
men was explored, and the entire ischemic segment 
plus a segment of proximal, nonischemic ileum was 
excised for histologic examination. The 8 cm long 
ischemic segment was sampled in three locations 
(proximal, midpoint, and distal), such that the 
proximal sample was taken at the periphery of the 
segment and the distal sample was taken 1 cm closer 
to the middle. These samples and the nonischemic 
segment were then fixed in 2.5% glutaraldehyde-0.1 
mol/L cacodylate buffer with 5% sucrose (pH 7.3) 
for 24 hours at 4 ° C. The rats were then killed with 
pentobarbital. This study was approved by the 
Institutional Animal Care and Use Committee of 
Dartmouth Medical School. 
Histologic assessment 
During pilot studies, we found that 110 minutes 
of segmental total ischemia, followed by 24 hours of 
reperfusion, resulted in severe intestinal ischemic 
injury, often with areas of total mucosal loss. To 
quantitate this injury, we developed five objective 
measurements of the degree of intestinal ischemia 
that correlated well with the overall blinded histo- 
logic evaluation by experienced observers. Transverse 
histologic sections of small intestine were prepared 
for light microscopy with toluidine blue-basic fuch- 
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Table I. Comparisons of control and glucagon-treated rats after segmental mesenteric ischemia 
Muscularis thickness (ram) Mucosal thickness (mm) Transmural thickness (mm) 
Glucagon Control Glucagon Control Glucagon Control 
Nonischemic  0 .09 -+ 0.01 0 .09 -+ 0.01 0 .39 _+ 0 .02*  0.43 -+ 0.01 0 .52 -+ 0 .02*  0 .57  -+ 0.01 
Prox imal  ischemic 0.11 _+ 0.02 0 .09 +_ 0 .02 0.28 + 0 .04*  0.15 _+ 0.03 0.45 _+ 0 .05*  0.28 _+ 0.05 
Midpor t ion  ischemic 0 .10 + 0.01 0.08 -+ 0.01 0.21 + 0 .04*  0 .10 + 0,01 0.35 + 0 .05*  0.21 _+ 0.01 
Distal  ischemic 0 .10 _+ 0.01 0 .09  -+ 0.01 0.23 _+ 0.03 ~ 0.11 +_ 0.01 0 .39 +_ 0 .04*  0.25 + 0.03 
Values are mean _+ SEM. 
*p _< 0.05, glucagon versus control. 
tp < 0.01, glucagon versus control. 
sin staining from each of the four segments described 
above. Sections were mounted to contain the ntire 
ileal circumference of these rats. Each microscopic 
section was projected onto a computerized planime- 
ter (Micro-Plan II; Laboratory Computer Systems, 
Inc., Cambridge, Mass.) for histologic measurement. 
The thickness of the intestinal wall was measured at 
25 to 30 points distributed around the circumference 
of each transverse section, and the average of these 
measurements was calculated. Measurement points 
were selected uniformly by making three measure- 
ments in standard positions i  each microscopic field 
of view around the circumference. This was necessary 
to average the variation observed in the severity of 
injury in each section. With this method, the total 
wall thickness was measured, as well as the thickness 
of the mucosa and the muscularis components 
(Fig. 1). In addition to wall thickness, the percentage 
of the circumference of the intestine that was covered 
with intact mucosal epithelium was measured and 
expressed as percent epithelial coverage. Finally, the 
villar surface area was estimated by measuring the 
total length of the villus circumference in these 
transverse projections. To standardize villa surface 
length for differing sizes of intestine, the total villus 
circumference was divided by the circumference at 
the villus-crypt junctions of that intestinal segment, 
expressed as the villar surface ratio (Fig. 1). 
Statistical analysis 
Unpaired t tests asstuning unequal variance were 
used to determine significant differences ofhistologic 
measurements between glucagon-treated and control 
animals and between onischemic and ischemic intes- 
tinal segments. Significance was accepted if two- 
tailedp < 0.05. 
RESULTS 
Nonischemic ileum in both control and gluca- 
gon-treated rats demonstrated normal morphology 
(Fig. 2, A). Epithelial coverage was 100% in all 
nonischemic segments, and the villar surface ratio 
was 3.0 to 3.1 (Table I). In glucagon-treated rats, the 
nonischemic mucosal and thus transmural i eal thick- 
ness was slightly less than that of control rats, whereas 
muscularis thickness was identical in both groups 
(Table I). 
Ischemic segments of control animals demon- 
strated severe histologic injury (Fig. 2, B). The 
muscularis thickness was the only objective param- 
eter that was unaffected by ischemia (Table I). 
Mucosal thickness was reduced substantially in these 
ischemic segments (p < 0.01), a result of sloughing 
of nearly all the villi. The ischemic injury was worst 
in the midpoint of the ischemic segments, where 
mucosal thickness was reduced to less than 25% of 
nonischemic ileum (Fig. 3). This resulted in a 
reduction in transmural wall thickness to less than 
half of  the nonischemic value (p < 0.01), despite the 
unchanged muscularis thickness (Table I). Epithelial 
coverage was also reduced substantially by ischemia- 
reperfusion, from 100% to 23% in the midpoint of 
the ischemic segment in control animals (p < 0.01). 
Finally, the villar surface ratio was reduced from 3.0 
to 1.1 in control animals (p < 0.01), indicating the 
near-total loss of villi after the 110-minute interval of  
ischemia followed by 24 hours of reperfusion. 
Variability was noted in the severity of ischemia 
around the circumference of each intestinal segment. 
Severity of injury was not well correlated with the 
mesenteric or antimesenteric side of the samples. In 
addition, there was variation between the proximal, 
midpoint, and distal samples of the 8 cm ischemic 
segment, such that the midpoint was the most 
ischemic. The distal sample, which was 1 cm closer to 
the midpoint, was somewhat more injured than the 
proximal sample, which was at the margin of the 
ischemic segment. 
Glucagon treatment for 2 hours after release of 
intestinal ischemia resulted in a substantial reduction 
in the histologic injury caused by ischemia-reper- 
fusion. This was apparent in all objective measure- 
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% Epithelial coverage Villar/surface ratio 
Glucagon Control Glucagon Control 
100 ± 0 100 -+ 0 2.95 ± 0.12 3.13 ± 0.14 
91 .4  -+ 5.3 ~ 45 .7  - 14.7 1.60 ± 0 .17  1.24 ± 0.19 
57.8 ± 14.4 ~ 22.5 ± 7.9 1.19 ± 0.10 ~ 1.05 -+ 0 .02 
68.6  ± 12 .9t  23.3 ± 8.0 1.35 ± 0.10 ~ 1.04 ± 0.02 
ments, as well as by visual inspection of the mi- 
croscopic sections (Fig. 2, C). Mucosal thickness 
was preserved to more than double the value in 
control animals (p < 0.05), which resulted in a 
substantial increase in transmural wall thickness 
compared with control animals, despite unchanged, 
normal muscularis thickness (Fig. 3; Table I). Epi- 
thelial coverage was increased to 58% in the mid- 
point of ischemia in glucagon-treated animals, more 
than  double the residual epithelial coverage in 
control animals (p < 0.05; Fig. 4). Finally, the 
villar surface ratio was also increased significantly in 
glucagon-treated animals compared with control 
animals (1o < 0.05), even though there was a 
marked reduction compared with nonischemic n- 
testine (Fig. 5). 
Histologic examination of the mucosal epithelial 
cells in glucagon-treated rats revealed a range of 
differentiation after ischemia. Some cells were vacu- 
olated and irregularly shaped and had prominent, 
large nuclei and nucleoli, suggesting early regenera- 
tion. Increased mitoses in the upper half of the villus 
crypts also suggested increased epithelial cell prolif- 
eration. However, many epithelial cells appeared 
columnar with intact microvilli, accompanied by 
goblet and Paneth's cells, suggesting preservation of
original epithelium. Thus both increased mucosal 
regeneration and preservation were observed after 
glucagon treatment. 
DISCUSSION 
In this study of segmental intestinal ischemia, 
intravenous glucagon given for 2 hours after ischemia 
substantially improved ileal mucosal viability when 
examined after 24 hours ofreperfusion. Although the 
difference between control and glucagon-treated 
animals was obvious to blinded observers, we used 
quantitative histologic measurements of intestinal 
injury to validate these visual impressions. These 
measurements demonstrated that glucagon reduced 
the ischemic injury of the mucosa by at least 50% 
compared with control animals, as indexed by 
mucosal thickness, percent epithelial coverage, and 
villar surface ratio. These three measurements proved 
most useful for discriminating different degrees of 
ischemic injury. Although previous investigators 
have used qualitative scoring systems to grade 
intestinal injury, we believe that this is the first use of 
quantitative histologic measurements. We fotmd that 
previous cales for grading intestinal injury, such as 
that of Chiu et al.,7 could not discriminate between 
the degrees of severe ischemia seen in our model, 
because most samples would be classified in the most 
severe stage of injury. 
Complete segmental ischemia for 110 minutes 
created severe mucosal injury in which to test the 
effect ofglucagon. This duration isknown to produce 
injury based mostly on ischemia, with little contri- 
bution from reperfusion i jury. 8 Use of a model of 
segmental, rather than total, SMA ischemia was 
important to ensure survival of the animals, such that 
histologic hanges could be interpreted without he 
confounding influence of circulatory arrest at death. 
Because 24-hour survival was observed in this 
segmental ischemia model, we do not believe that 
ischemic injury to less than 10% of the entire small 
bowel had any appreciable systemic hemodynamic 
effects, in marked contrast o the systemic shock 
observed after total SMA occlusion. However, we 
have not yet performed hemodynamic measurements 
in our segmental ischemia model. 
Although this study was not designed to define 
the mechanism ofglucagon's effect, several possibili- 
ties exist that remain to betested. Previous investi- 
gators have observed that vasoconstriction persists in 
the intestinal circulation after ischemia, especially if
the ischemic interval is prolonged or severe. 9-n I  a 
rabbit model of intestinal strangulation, Oshima et 
al.x0 demonstrated that ileal mucosal blood flow 
remained reduced after relief of ischemia, and flow 
was improved substantially b  intravenous glucagon. 
In a canine model we demonstrated that SMA blood 
flow remained low after release of a severe SMA 
stenosis but flow was normalized (as was cardiac 
output) by intravenous glucagon,  Finally, in our 
studies of total, transient SMA occlusion in rats, we 
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Fig. 1. Quantitative measurements of ileal ischemic-reperfusion injury performed by digitizing 
projected microscopic image with computerized planimeter, a Muscularis thickness; b, mucosal 
thickness; c, transmural thickness (each measured at 30 points around circumference in each 
section); d, percentage ofluminal circumference covered with mucosal epithelial cells; 6 villar 
surface circumference measured nd divided by bowel circumference at base of villi f,, to calculate 
villar surface ratio. 
Fig. 2. Representative transverse sections from onischemic leum (A) and ileum after 110 
minutes of ischemia nd 24 hours of reperfusion i  (B) glucagon-treated and ((2) control rats. 
Control rats showed near-total mucosal loss, with absent epithelial coverage (C), whereas 
glucagon-treated rats showed more mucosal preservation with epithelium often intact (B). 
(Original magnification × 160.) 
have demonstrated a marked hemodynamic effect of 
glucagon in restoring both cardiac output and SMA 
blood flow after intestinal reperfusion. 6 Thus there is 
substantial evidence that glucagon acts through 
selective mesenteric vasodilation, as well as cardiac 
inotropic support, to reduce the ischemic interval 
functionally by restoring normal blood flow earlier 
during reperfusion. These effects may be responsible 
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Fig. 3. Comparison of ileal mucosal thickness in control and glucagon-treated rats after 
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Fig. 4. Comparison of percentage of mucosa covered by epithelium in control and 
glucagon-treated rats after segmental mesenteric ischemia (mean -+ SEM). 
for the improved mucosal viability seen in our 
segmental model. 
There are, however, other possible mechanisms 
by which glucagon could achieve the salutary effects 
observed in this study. It is known that some mucosal 
regeneration occurs during the first 24 hours of 
observation after ischemic injury, t2 It has been 
suggested that glucagon may have a trophic effect on 
regenerating small bowel mucosa. 13 This could be a 
direct effect of the mucosa or an indirect effect of 
earlier estoration of blood flow necessary for regen- 
eration. The extent of atrophic effect of glucagon on 
intestinal mucosal regeneration requires further in- 
vestigation. 
In this initial study of segmental intestinal isch- 
emia, we chose to administer glucagon intrave- 
nously during the first 2 hours of reperfusion 
because this paradigm has substantially improved 
survival in our previous studies of total SMA 
occlusion in rats. 4 In these studies we found that 
glucagon administration before the release of SMA 
occlusion actually reduced survival rates, suggesting 
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Fig. 5. Comparison f villar surface ratio ofileal mucosa in control and glucagon-treated rats 
after segmental mesenteric ischemia (m an -+SEM). 
a "steal" phenomenon caused by vasodilating ad- 
jacent regions of nonischemic intestine and viscera. 
We are unable to test the influence of the timing 
of glucagon infusion on collateral flow in our 
segmental ischemic model because it was necessary 
to eliminate all collateral flow by clamping not only 
the ileal vascular arcades but also the ends of these 
bowel segments. We found that when the vascular 
arcades alone were clamped, sufficient collateral f ow 
through the bowel and adjacent marginal vessels 
persisted into this small segment, such that insig- 
nificant or variable ischemia occurred. Studies spe- 
cifically designed to test the effect of vasodilators 
on collateral flow during occlusive mesenteric isch- 
emia, however, suggest hat steal can occur in this 
setting. ~44s Thus we have chosen to focus on the 
potential advantages of glucagon administration 
after the relief of occlusive mesenteric ischemia, 
which has more theoretic (and practical) appeal than 
glucagon administration before relieving the vas- 
cular occlusion. 
Other investigators have examined the impact of 
intravenous glucagon on ischemic intestinal viability, 
with differing results. Clark and Gewertz 16 found that 
glucagon increased intestinal metabolism in an iso- 
lated rat intestinal preparation and exacerbated the 
subsequent ischemic injury. Because glucagon was 
administered before and during the ischemic interval, 
rather than only during reperfusion, however, the 
results of this study are not inconsistent with our 
findings. With a rabbit model of ileal strangulation, 
Oshima et al. a° found that intravenous glucagon 
administered after eperfusion improved small bowel 
viability as assessed by its fluorescence pattern but 
did not perform a quantitative analysis of the de- 
gree of improvement. Their study, however, is 
entirely consistent with the quantitative results we 
have obtained. 
The clinical relevance of these observations in a rat 
model of segmental intestinal ischemia is uncertain. 
There have been anecdotal reports of the adminis- 
tration of glucagon to patients with intestinal isch- 
emia, with salutary effects noted. 17,18 We have 
observed rapid improvement in intestinal color and 
Doppler waveforms after glucagon (1 mg intrave- 
nously) in several patients who appeared to have 
persistant ischemia after SMA embolectomy. 2 Fur- 
ther studies are required, however, to validate such 
anecdotal observations. Thus we would urge caution 
in the use of glucagon in patients with mesenteric 
ischemia. However, the significant improvement in
mucosal viability seen in our animal study provides 
impetus for the further study of glucagon in this 
setting. 
We appreciate the histopathologic expertise and advice 
of Vincent A. Memoli, MD, and Robert M. Zwolak, MD, 
PhD, and the technical assistance of Mr. Alfred Gauthier 
during the performance ofthis study. 
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D ISCUSSION 
Dr. John Herrmann (Worcester, Mass.). In preparing 
for this discussion I did a MedLine search. I found about 
2600 articles on glucagon in the past 5 years, 111 articles 
on mesenteric ischemia, and only four articles on the 
combination of the two, glucagon and intestinal ischemia. 
Two of those articles came from the Dartmouth group, so 
I think Dartmouth represents he forefront of research in 
this area. 
Mesenteric ischemia is still a major clinical problem. 
We have a mortality rate of 70% to 90% treating patients 
with this disease. It is not a common problem but it 
certainly isnot rare. It is estimated that somewhere between 
one in 1000 and one in 5000 hospital admissions are 
patients with intestinal ischemia. Some physicians have 
actually said that intestinal ischemia has replaced pneumo- 
nia as the old man's friend. 
Late diagnosis remains the major clinical cause of 
death. Neither glucagon or any other magic elixir is going 
to salvage necrotic bowel. There are, however, anumber of 
patients who die of multiorgan system failure despite what 
seems to be prompt and adequate mesenteric revascular- 
ization. Loss of the intestinal mucosal barrier with bacterial 
invasion has been implicated as one of the factors in the 
poor outcome in these patients. A mechanism for limiting 
mucosal damage would be a welcome addition to our 
clinical armamentarium. It is obviously too early to 
advocate the use of glucagon in the clinical area, although 
you describe several anecdotal cases that have been 
reported. 
Have you attempted to reproduce these results in any 
other animal model? The rat and other odents are different 
from humans in that they normally have bacteria in their 
intestinal circulation. Have you tried it on guinea pigs or 
other animals with sterile portal venous blood? Second, 
glucagon is a complex hormone with many physiologic and 
pharmacologic effects. YOU have postulated that the 
protective ffect of glucagon is the result of vasodilation, 
possibly in conjunction with an inotropic effect on the 
heart. Have you compared glucagon with papaverine or 
other more commonly used vasodilators in this model? 
Would you also comment on the possibility of the use of 
glucagon in the treatment of nonocclusive mesenteric 
ischemia, which may be in part due to intestinal vascular 
constriction and reduced cardiac output? 
Mr. Sidhu P. Gangadharan. We have not yet tried to 
reproduce these resuks in a different animal model. We 
selected the rat for these initial histologic studies because 
our previous urvival studies were done in rats. However, 
Oshima et a1.1° reported similar esults in a rabbit model in 
which qualitative histologic improvement was seen after 
glucagon administration after segmental mesenteric isch- 
emia. Previous hemodynamic studies performed in dogs in 
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our laboratories also suggest that these effects of glucagon 
are not species specific. 
In terms of the mechanism of effect, you are correct that 
glucagon has physiologic function in addition to vasodila- 
tion and inotropic support. There is some suggestion that 
glucagon may have a trophic effect hat enhances intestinal 
regeneration, as discussed in our article. We have not yet 
compared glucagon with other commonly used vasodila- 
tors, such as papaverine, because these cause nonselective 
systemic vasodilation when administered intravenously, in 
contrast o the more selective mesenteric vasodilation 
produced by glucagon. It would be possible to compare the 
effect ofglucagon with intraarterial dministration f these 
nonselective vasodilators in a large animal model, but we 
have not yet performed these experiments. Thus at the 
present time we are uncertain whether the beneficial effects 
of glucagon seen after segmental ischemia are due to its 
hemodynamic vasodilating properties or to other proper- 
ties such as trophic effects that might enhance regeneration. 
Finally, in terms of nonocclusive ischemia caused by 
intestinal vasoconstriction and reduced cardiac output, 
glucagon would theoretically appear to be an ideal phar- 
macologic treatment. We have demonstrated substantial 
improvement in a canine model of nonocclusive ischemia 
after glucagon administration but are unaware of any 
clinical trials that have validated this potential benefit of 
glucagon treatment. 
Dr. Sang Cho (Boston, Mass.). When we have organ 
damage caused by ischemia, the damage occurs during the 
ischemic period, reperfusion period, or both periods 
depending on which organs are involved in ischemia. The 
small bowel contains a high level of xanthine oxidase 
activity. Therefore I suspect hat most of the ischemic 
damage to the small bowel occurs during the reperfusion 
period. Do you think that you may have been able to 
preserve small bowel more effectively if you have used free 
oxygen radical scavengers o  a calcium channel blocker in 
your study? 
Mr. Gangadharan. You are correct hat the extent of 
ischemic versus reperfusion i jury depends on not only the 
length ofischemia but also the specific organ studied. Based 
on previous tudies of ischemic time and intestinal injury, 
we would estimate that the total ischemic time of 110 
minutes that we employed would emphasize ischemic 
rather than perfusion injury. However, we have not yet 
specifically quantitated this effect by examining intestinal 
histologic findings immediately after ischemia. We selected 
glucagon for use in this tudy because it had conferred 
substantial survival benefit in our previous tudies, whereas 
calcium channel blockers and free radical scavengers were 
unable to do so. We have not directly compared the 
histologic changes after glucagon administration with 
calcium channel blockade or free radical scavengers in this 
model, however. 
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